NFL BIOSCIENCES, which is committed to the fight against smoking, fully supports World No Tobacco Day on May 31
May 25 2022 - 1:00AM
NFL BIOSCIENCES, which is committed to the fight against smoking,
fully supports World No Tobacco Day on May 31
NFL BIOSCIENCES, which is committed to the fight against
smoking, fully supports World No Tobacco Day on May 31
NFL BIOSCIENCES, a biopharmaceutical
company developing botanical drugs for the treatment of addictions,
including NFL-101, a smoking cessation aid drug candidate currently
in a Phase II/III clinical trial in France, fully endorses the
message and call to action for World No Tobacco Day on May 31,
2022, led by the World Health Organization, with environmental
protection as this year’s theme.
The World Health Organization (WHO) launched
World No Tobacco Day in 1987 to help build increased awareness
worldwide of the smoking epidemic and its potentially deadly
effects. Smoking is the biggest avoidable epidemic facing
healthcare professionals, and the tobacco industry also has harmful
impacts in terms of the environment and climate, as highlighted by
the WHO in its annual campaign #TobaccoExposed1.
This year, the WHO has chosen to highlight tobacco’s impact on the
environment: 600 million trees have been chopped down and 22
billion liters of water are needed to produce cigarettes, while 84
million tons of CO2 have been released into the atmosphere,
contributing to the rise in temperatures around the world, not to
mention the widespread waste, toxins and microplastic pollution
resulting from the production and consumption of tobacco.
Looking beyond the environmental damage and
climate impacts, tobacco is of course a global public health issue.
1.3 billion people smoke around the world and tobacco results in
more than 8 million deaths each year, including 75,000 in France.
The costs in terms of healthcare and loss of productivity due to
premature deaths and illnesses are considerable: 2,000 billion
dollars per year. 2
As highlighted by the WHO in its call to action,
stopping smoking has beneficial effects for people’s health and the
environment.
Bruno Lafont, Chief Operating Officer and
co-founder of NFL Biosciences: “In the last few years, there has
been a real increase in awareness of the negative impacts of
tobacco on people’s health and the environment, as well as its
human and financial costs for society worldwide. Both individually
and collectively, from public authorities to businesses and civil
society, we all have a duty to take action and support the
initiatives to fight against smoking and its disastrous
consequences. At NFL Biosciences, fighting addictions is what
guides us every day, and we have chosen to develop innovative
botanical drugs to help people who would like to stop smoking. This
is where our expertise is driving progress in order to meet these
challenges for future generations”.
While stopping smoking is difficult, there are
solutions available and biopharmaceutical companies like NFL
Biosciences are fully committed to this fight. For reference, NFL
Biosciences is currently conducting the Cesto 2 study, a Phase
II/III clinical trial for NFL-101, its innovative botanical drug
candidate for smoking cessation, approved by the French National
Agency for the Safety of Medicines and Health Products (ANSM)3 and
the Ethics Committee. NFL-101 is a nicotine-free extract from
tobacco leaves. The Clinical Investigation Centers (CIC) at the CHU
teaching hospital centers in Rennes, Poitiers and Bordeaux are
currently recruiting volunteers: adults who smoke more than 11
cigarettes per day and are genuinely committed to stopping. Another
four CHU hospital centers are also joining the recruitment program.
The aim is to recruit 318 candidates to carry out this study on the
French scope.
About
NFL Biosciences
NFL Biosciences is a biopharmaceutical company
based in the Montpellier area which develops botanical drug
candidates for the treatment of addictions. NFL Biosciences'
ambition is to bring new, natural, safer and more effective
therapeutic solutions to the entire world population, including
low- and middle-income countries. Its most advanced product, called
NFL-101, is a standardized, nicotine-free tobacco leaf extract
protected by two patent families. NFL Biosciences intends to offer
smokers who want to quit a natural, safe, easy-to-administer and
personalized alternative. NFL Biosciences is also developing
NFL-301, a natural drug candidate for the reduction of alcohol
consumption and has a drug development project for the treatment of
cannabis use disorders.
The shares of NFL Biosciences are listed on
Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at
www.nflbiosciences.com Contacts
Bruno Lafont – info@nflbiosciences.com - 04 11
93 76 67 Agence
Calyptus – nflbio@calyptus.net - 01 53 65 68 68
1 https://www.who.int/fr/campaigns/world-no-tobacco-day/20222
https://tobaccoatlas.org and WHO (2021)3 Agence Nationale de
sécurité du médicament et des produits de santé
- NFLBiosciences_Journée sans tabac_EN_def
NFL Biosciences (EU:ALNFL)
Historical Stock Chart
From Jul 2024 to Aug 2024
NFL Biosciences (EU:ALNFL)
Historical Stock Chart
From Aug 2023 to Aug 2024